Research Topics<\/h2>\n
We are highly focused on developing quantitative translational regulators of proteins role in solid tumors. Discoveries made in molecular studies and proteomics progression are rapidly translated for application at the bedside. We have partnered with biotech and pharmaceutical companies in developing treatment protocols and new molecular oncology approaches, the results of which may increase overall survival and eventually expedite development of a cure for patients with solid tumor cancers.<\/p>\n
Main Projects<\/h3>\n![\"\"](\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2024\/02\/Translational-molecular-research-nanostring-2024.jpg\")
Translational Molecular Research using Nano String technology – Saint John’s Cancer Institute<\/figcaption><\/figure>\n\n- We are assessing for molecular blood biopsies in blood and urine that include cell-free nucleic acids (cfNAs) (DNA, miRNA) and CTCs and exosomes. We assess\/determine their clinical utility especially in diagnosis and prognosis during follow up of treatment.<\/li>\n
- We assess cfNA and exosomes in patients who receive immune checkpoint inhibitor therapies.<\/li>\n
- We identify various forms of epigenetic changes (methylation and histone) as related to metastasis and therapy resistance.<\/li>\n
- Our dept. assesses DNA Damage Resistance (DDR) solid tumors.<\/li>\n
- We examine primary and extracranial brain tumor cFNA and molecular biology for progression-related genes.<\/li>\n
- Our Dept has focused on proteomics as related to activity during tumor progression and DDR, specifically regulatory mechanisms of specific ubiquilin and ubiquitins.<\/li>\n
- Our studies also focus on molecular immune responses during treatment using our new approaches of spatial biology and single cell sequencing.<\/li>\n<\/ul>\n","layer_is_content_auto_columns":false,"sidebar_position":"right","widgets":false,"layer_icon":"","layer_icon_position":"left","layer_background_color":"","layer_id":""},{"acf_fc_layout":"layer_content_sidebar","layer_label":"","layer_headline":"","layer_intro":"","layer_content":"
Partnership & Collaboration<\/h2>\n
![\"academic-and-industry-collborations-saint-johns-cancer-institute](\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/09\/academic-and-industry-collborations-saint-johns-cancer-institute-2021.jpg\")
<\/p>\n
<\/div>\nOur Translational Molecular Medicine Department collaborates with academic and industry partners to fulfill our translational research goals. Our academic partners help build programs, sharing knowledge and resources for the benefit of all partners, while our industry partners help us develop products and provide resources not available at the institute. The department has been supported by NIH\/NCI grants for melanoma translational studies since 1992 while support for breast cancer has been provided by FFANY, ABC, Gonda, California Breast Cancer Program, DOD, and Komen foundations. Studies in prostate cancer have been supported by ABC foundation and DOD in the past. Recent support in the last 8 years has been provided by the Adeleson Medical Research Foundation (AMRF), which includes projects related to DDR, Molecular Immunology, and Brain Metastasis as well as Epigenetic Sequence Platform Core. Additional major grant support include NCI Melanoma SPORE from the University of Penn, S. Riley Early Detection Pancreas Cancer, MiNk Therapeutics, Merck, BioDyne Inc., and the NIH NCI Preventative ROI Clinical Trial grant with the City of Hope, Duarte, CA. We are member of melanoma Melanoma SPORE: University of Pennsylvania\/Wistar Institute.<\/p>\n
Currently, the members of the department are organized in different sections of research, these include: <\/strong><\/p>\n\n- The identification of cfNA and exosomes in blood and urine for diagnosis and prognosis of patients during follow-up. <\/span><\/li>\n
- The understanding of epigenetic mechanisms that regulate regional and distant(brain, visceral organ) metastasis.<\/span><\/li>\n
- Assessment of ubiquitin and ubiquilin protein regulatory pathways that promote tumor progression and treatment resistance.<\/span><\/li>\n
- Identification of mechanisms of primary brain and brain metastasis progression and tumor microenvironment interactions.<\/span><\/li>\n<\/ol>\n
\n- See Principle Collaborators<\/a> <\/strong><\/li>\n<\/ul>\n","layer_is_content_auto_columns":false,"sidebar_position":"right","widgets":false,"layer_icon":"","layer_icon_position":"left","layer_background_color":"bg-none","layer_id":""},{"acf_fc_layout":"layer_content_sidebar","layer_label":"","layer_headline":"","layer_intro":"","layer_content":"
![\"Ling](\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2025\/03\/Ling-Translational-Award-2025-scaled.jpg\")
The Molecular Research Team and Fellows at Saint John’s Cancer Institute<\/figcaption><\/figure>\nPostdoctoral Lab-Based Translational Molecular Medicine Fellowship<\/h2>\n
As pioneers in translational studies on \u201cmolecular fluid\u201d involving various cfNA in multiple types of solid tumors, the fellowship program also consists of studying epigenetic mechanisms, and DDR regulating solid tumors as well as pharmacogenomics and immunogenomic-based prediction of responses to therapy.<\/p>\n
Learn more about the Molecular Oncology Fellowship<\/a><\/strong><\/p>\nNews and Events<\/h2>\n
We have received a renewal of our three-year, multi-million-dollar grant from the Sheldon and Miriam Adelson Medical Research Foundation (AMRF), effective October 1, 2025. This award supports multiple national and international collaborations with major cancer centers.<\/strong>
\n<\/p>\n\nAMRF Projects<\/h3>\n\n- Epigenomic and Oncogenic Drivers of Melanoma Metastasis and Therapy Resistance<\/strong><\/li>\n
- APCR\/APMMR Shared Epigenomics Resources<\/strong><\/li>\n<\/ol>\n
2024 & 2025 Conferences<\/h3>\n
![\"Tri-Con](\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2023\/02\/Tri-Con-SanDiego-March-6)
<\/a><\/p>\n\n- Seminar, New Melanoma Molecular Genetics Studies, Dept. Translational Molecular Medicine SJCI: January 1, 2024(Los Angeles, California)<\/strong> Speaker: Wistar Institute & University of Penn Melanoma Group.<\/li>\n
- Global Professor Seminar: Molecular and Spatial Analysis of Early Onset Colorectal Cancer (EOCRC): March, 2024 (Tokyo, Japan)<\/strong> – Speaker: Keio University of Surgery, Japan.<\/li>\n
- The 20th Ataxia-Telangiectasia Workshop March 3, 2024 (Tokyo, Japan) <\/strong> – Speaker: UBQLN4 Triggers MRE11a and STING Proteasomal Degradation During Cisplatin induced DNA Damage Response in ESCC and TNBC.<\/li>\n
- Molecular Medicine Tri-Con (31st Annual): March, 2024 (San Diego, CA)<\/strong> – Chairman and Speaker: Liquid Biopsy Biomarkers for Patient Selection and Treatment Monitoring. CFDNA ILF2 Amplification Utility in Monitoring Melanoma Patients Receiving Checkpoint Inhibitor Immunotherapy. <\/li>\n
- New Approaches in Epigenetic Platform NGS Assays: August, 2024 (Philadephia, PA)<\/strong> Dept. Obstetrics Gynecology, University of Penn.<\/li>\n
- Impact of ATM Expression on Immune Checkpoint Inhibitor Efficacy and Prognosis in Metastatic Melanoma Patients: October, 2024 (Shenzhen, China)<\/strong> ATW-2024<\/li>\n
- Special lecture: Translational Research for Surgeons. 86th Annual Congress. November, 2024 (Utsunomiya, Japan)<\/strong> Speaker: Japan Surgical Association<\/li>\n
- Presentation: Spatial Analysis of Tumor Microenvironment of Melanoma Metastasis Using NanoString GeoMx and Akoya. November, 2024 (Boston, MA)<\/strong> Speaker: Adelson Medical Research Foundation Meeting.<\/li>\n
- Presentation: Predictive Genes Signature In Primary Prostate Cancer Association with Regional Lymph-Node Metastasis Using Both mRNA and miRNA Profiling. December, 2024 <\/strong> Speaker: ESMO Asia.<\/li>\n
- Invited Speaker: Liquid Biopsy cfmiRNA. September, 2025 (Greece)<\/strong> ACTC<\/li>\n
- Invited Speaker: Liquid Biopsy cfmiRNA. December, 2025 (Hong Kong)<\/strong> CNAPS<\/li>\n<\/ul>\n<\/div>\n
Positions Available<\/h2>\n
The Department is looking for postdoctoral fellows who have experience in translational molecular CTC and cfNA research. Also postdoctoral fellows experience in Cancer Epigenetics as well as metastasis regulatory mechanisms.<\/p>\n
Contact:<\/h4>\n
<\/p>\n
Irene Ramos, MSc, Translational Molecular Medicine Department Laboratory Manager
\n<\/strong>Romela.Ramos@providence.org<\/a><\/p>\n","layer_is_content_auto_columns":false,"sidebar_position":"right","widgets":false,"layer_icon":"","layer_icon_position":"left","layer_background_color":"bg-gray-l","layer_id":""},{"acf_fc_layout":"layer_people","layer_label":"","layer_headline":"Molecular Personnel ","layer_intro":"","people":{"950":{"id":950,"title":"Irene Ramos, MSc"},"6358":{"id":6358,"title":"Tianyu Chen, MD"},"5893":{"id":5893,"title":"Kelly Chong, Ph.D"},"951":{"id":951,"title":"Ling Takeshima"},"3980":{"id":3980,"title":"Jose Catbagan Jr."},"3037":{"id":3037,"title":"Shanty Chenathukattil"},"5135":{"id":5135,"title":"Jamie Moon"},"5895":{"id":5895,"title":"SooMin Kim"},"6008":{"id":6008,"title":"Sheryll Aquinde"},"6321":{"id":6321,"title":"Kodai Abe, MD, PhD"},"6319":{"id":6319,"title":"Kazuaki Okamoto, MD, PhD"},"6775":{"id":6775,"title":"Jason Mooney"}},"layer_people_more_link":"","layer_background_color":"","layer_id":""},{"acf_fc_layout":"layer_content_image","layer_label":"","layer_headline":"","layer_content":"Publications<\/h2>\nKey Recent Manuscripts<\/h3>\n\n- Clonal dynamics shaped by diverse drug-tolerant persister states in melanoma resistance.<\/strong><\/a>. Mol Cancer. 2026 Mar 3. doi: 10.1186\/s12943-026-02622-9. PMID: 41776501\n<\/li>\n
- Ubiquitin E3 ligase KPC1 governs mesenchymal metastatic melanoma reprogramming via proteasomal degradation of ZEB1<\/strong><\/a>. Cell Death Dis. 2025 Dec 22;16(1):897. doi: 10.1038\/s41419-025-08262-z.\n<\/li>\n
- Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes<\/strong><\/a>.JCO Oncology Advances. In Press 2025.<\/li>\n
- Interruption of the Intratumor CD8: Treg Crosstalk Improves the Efficacy of PD-1 Immunotherapy.<\/strong><\/a> Cancer Cell. Jun 10;42:1051-1066.e7. doi: 10.1016\/j.ccell.2024.05.013, 2024.<\/li>\n
- Interferon-induced factor 16 is essential in metastatic melanoma to maintain STING levels and the immune responses upon IFN-\u03b3 response pathway activation.<\/strong><\/a> J Immunotherapy Cancer. Oct 18;12(10):e009590. doi: 10.1136\/jitc-2024-009590, 2024.<\/li>\n
- Induced collagen type-I secretion by hepatocytes of the melanoma liver metastasis is associated with a reduction in tumour-infiltrating lymphocytes.<\/strong><\/a> Clin Transl Med. Nov;14(11):e70067. doi: 10.1002\/ctm2.70067, 2024.<\/li>\n
- Repurposing colforsin daropate to treat MYC-driven high-grade serous ovarian carcinomas.<\/strong><\/a> Sci Signal. Nov 19;17(863):eado8303. doi: 10.1126\/scisignal.ado8303, 2024.<\/li>\n
- Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation. Cancer Cell.<\/strong><\/a> Dec 9;42(12):1985-1987. doi: 10.1016\/j.ccell.2024.10.017, 2024.<\/li>\n
- Diagnostic miRNA Signatures in Paired Tumor, Plasma, and Urine Specimens From Renal Cell Carcinoma Patients.<\/strong><\/a> Clin Chem. 2024 Jan 4;70(1):261-272. doi: 10.1093\/clinchem\/hvad133.<\/li>\n
- MRI-derived radiomics assessing tumor-infiltrating macrophages enable prediction of immune-phenotype, immunotherapy response and survival in glioma<\/strong><\/a> Biomark Res. 2024 Jan 31;12(1):14. doi: 10.1186\/s40364-024-00560-6.<\/li>\n
- Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells<\/strong><\/a> JCI Insight. 2024 Mar 8;9(5):e170961. doi: 10.1172\/jci.insight.170961.<\/li>\n
- Preanalytical considerations in quantifying circulating miRNAs that predict end-stage kidney disease in diabetes<\/strong><\/a> JCI Insight. 2024 Jun 24;9(12):e174153. doi: 10.1172\/jci.insight.174153.<\/li>\n
- Tissue-specific thresholds of mutation burden associated with anti-PD-1\/L1 therapy benefit and prognosis in microsatellite-stable cancers<\/strong><\/a> Nat Cancer. 2024 Jul;5(7):1121-1129. doi: 10.1038\/s43018-024-00752-x. Epub 2024 Mar 25.<\/li>\n
- Smoking Status and Survival in Patients With Early-Stage Primary Cutaneous Melanoma<\/strong><\/a> JAMA Netw Open. 2024 Feb 5;7(2):e2354751. doi: 10.1001\/jamanetworkopen.2023.54751.<\/li>\n
- Spatial profiling of cancer-associated fibroblasts of sporadic early onset colon cancer microenvironment<\/strong><\/a> NPJ Precis Oncol. 2023 Nov 14;7(1):118. doi: 10.1038\/s41698-023-00474-w.<\/li>\n
- Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases<\/strong><\/a> NPJ Precis Oncol. 2023 Nov 14;7(1):120. doi: 10.1038\/s41698-023-00471-z.<\/li>\n
- Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma.<\/strong><\/a> Clin Cancer Res, 28, 1911\u201324, 2022.<\/li>\n
- Topical therapy for regression and melanoma prevention of congenital giant nevi.<\/strong><\/a> Cell, 185, 2071\u201385. e12, 2022.\n
- Integrated analysis of plasma and single immune cells uncovers metabolic changes in individuals with COVID-19<\/strong><\/a>. Nat Biotechnol. 2022 Jan;40(1):110-120. doi: 10.1038\/s41587-021-01020-4.<\/li>\n
- Multi-modal molecular programs regulate melanoma cell state.<\/strong><\/a> Nat Commun. 2022 Jul 9;13(1):4000. doi: 10.1038\/s41467-022-31510-1.<\/li>\n
- IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer.<\/strong><\/a> Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2201376119. doi: 10.1073\/pnas.2201376119.<\/li>\n<\/ul>\n","layer_link":"","layer_img":1448,"layer_img_position":"left","layer_img_size":"cover","layer_img_is_fade":false,"layer_background_color":"bg-gray-l","layer_id":""}],"int_alt_page_title":"","int_page_description":"","int_masthead_image":false,"int_page_icon":"","int_secondary_cta_override":false,"int_secondary_cta_is_hidden":true,"hero_group":{"":null,"layer_hero_headline":"Translational Molecular Medicine Research","layer_hero_excerpt":"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses. Our team translates promising therapeutics from bench to bedside treatment for solid tumors, particularly melanoma, breast cancer, GU cancer, GI tract cancers and brain tumors.","layer_hero_link":"","layer_hero_images":[{"layer_hero_img":{"ID":1210,"id":1210,"title":"translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide","filename":"translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-scaled.jpg","filesize":372079,"url":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-scaled.jpg","link":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide\/","alt":"Translational Molecular Medicine - Bio-Markers - Saint John's Cancer Institute","author":"62","description":"","caption":"","name":"translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide","status":"inherit","uploaded_to":387,"date":"2021-05-10 21:49:01","modified":"2021-05-10 21:49:11","menu_order":0,"mime_type":"image\/jpeg","type":"image","subtype":"jpeg","icon":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-includes\/images\/media\/default.png","width":2560,"height":1190,"sizes":{"thumbnail":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-150x150.jpg","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-300x139.jpg","medium-width":300,"medium-height":139,"medium_large":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-768x357.jpg","medium_large-width":768,"medium_large-height":357,"large":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-1024x476.jpg","large-width":1024,"large-height":476,"1536x1536":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-1536x714.jpg","1536x1536-width":1536,"1536x1536-height":714,"2048x2048":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-2048x952.jpg","2048x2048-width":2048,"2048x2048-height":952,"blog-author-thumbnail":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-150x150.jpg","blog-author-thumbnail-width":150,"blog-author-thumbnail-height":150,"lowres":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-100x46.jpg","lowres-width":100,"lowres-height":46,"square-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-480x480.jpg","square-md-width":480,"square-md-height":480,"rectangle-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-550x300.jpg","rectangle-md-width":550,"rectangle-md-height":300,"16x9-xs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-480x270.jpg","16x9-xs-width":480,"16x9-xs-height":270,"masthead":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-1440x400.jpg","masthead-width":1440,"masthead-height":400,"hero":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-1440x835.jpg","hero-width":1440,"hero-height":835,"hero-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-1024x768.jpg","hero-md-width":1024,"hero-md-height":768,"hero-sm":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-768x320.jpg","hero-sm-width":768,"hero-sm-height":320,"hero-xs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-460x260.jpg","hero-xs-width":460,"hero-xs-height":260,"hero-xxs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-320x260.jpg","hero-xxs-width":320,"hero-xxs-height":260,"gform-image-choice-sm":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-scaled.jpg","gform-image-choice-sm-width":300,"gform-image-choice-sm-height":139,"gform-image-choice-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-scaled.jpg","gform-image-choice-md-width":400,"gform-image-choice-md-height":186,"gform-image-choice-lg":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-scaled.jpg","gform-image-choice-lg-width":600,"gform-image-choice-lg-height":279}}},{"layer_hero_img":false},{"layer_hero_img":{"ID":1246,"id":1246,"title":"HTG-Edge-Sequencing--saint-johns-cancer-institute","filename":"HTG-Edge-Sequencing-saint-johns-cancer-institute.jpg","filesize":714300,"url":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute.jpg","link":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/htg-edge-sequencing-saint-johns-cancer-institute\/","alt":"Genetic Sequencing -Saint Johns Cancer Institute","author":"62","description":"","caption":"","name":"htg-edge-sequencing-saint-johns-cancer-institute","status":"inherit","uploaded_to":387,"date":"2021-05-17 21:27:37","modified":"2021-05-17 21:28:24","menu_order":0,"mime_type":"image\/jpeg","type":"image","subtype":"jpeg","icon":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-includes\/images\/media\/default.png","width":2074,"height":1555,"sizes":{"thumbnail":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-150x150.jpg","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-300x225.jpg","medium-width":300,"medium-height":225,"medium_large":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-768x576.jpg","medium_large-width":768,"medium_large-height":576,"large":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-1024x768.jpg","large-width":1024,"large-height":768,"1536x1536":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-1536x1152.jpg","1536x1536-width":1536,"1536x1536-height":1152,"2048x2048":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-2048x1536.jpg","2048x2048-width":2048,"2048x2048-height":1536,"blog-author-thumbnail":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-150x150.jpg","blog-author-thumbnail-width":150,"blog-author-thumbnail-height":150,"lowres":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-100x75.jpg","lowres-width":100,"lowres-height":75,"square-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-480x480.jpg","square-md-width":480,"square-md-height":480,"rectangle-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-550x300.jpg","rectangle-md-width":550,"rectangle-md-height":300,"16x9-xs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-480x270.jpg","16x9-xs-width":480,"16x9-xs-height":270,"masthead":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-1440x400.jpg","masthead-width":1440,"masthead-height":400,"hero":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-1440x835.jpg","hero-width":1440,"hero-height":835,"hero-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-1024x768.jpg","hero-md-width":1024,"hero-md-height":768,"hero-sm":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-768x320.jpg","hero-sm-width":768,"hero-sm-height":320,"hero-xs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-460x260.jpg","hero-xs-width":460,"hero-xs-height":260,"hero-xxs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-320x260.jpg","hero-xxs-width":320,"hero-xxs-height":260,"gform-image-choice-sm":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute.jpg","gform-image-choice-sm-width":300,"gform-image-choice-sm-height":225,"gform-image-choice-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute.jpg","gform-image-choice-md-width":400,"gform-image-choice-md-height":300,"gform-image-choice-lg":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute.jpg","gform-image-choice-lg-width":600,"gform-image-choice-lg-height":450}}},{"layer_hero_img":{"ID":1245,"id":1245,"title":"HTG-molecular-saint-johns-cancer-institute","filename":"HTG-molecular-saint-johns-cancer-institute.jpg","filesize":1361052,"url":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute.jpg","link":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/htg-molecular-saint-johns-cancer-institute\/","alt":"HTG Molecular Saint Johns Cancer Institute","author":"62","description":"","caption":"","name":"htg-molecular-saint-johns-cancer-institute","status":"inherit","uploaded_to":387,"date":"2021-05-17 20:23:08","modified":"2021-05-17 20:25:16","menu_order":0,"mime_type":"image\/jpeg","type":"image","subtype":"jpeg","icon":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-includes\/images\/media\/default.png","width":2074,"height":1172,"sizes":{"thumbnail":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-150x150.jpg","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-300x170.jpg","medium-width":300,"medium-height":170,"medium_large":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-768x434.jpg","medium_large-width":768,"medium_large-height":434,"large":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-1024x579.jpg","large-width":1024,"large-height":579,"1536x1536":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-1536x868.jpg","1536x1536-width":1536,"1536x1536-height":868,"2048x2048":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-2048x1157.jpg","2048x2048-width":2048,"2048x2048-height":1157,"blog-author-thumbnail":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-150x150.jpg","blog-author-thumbnail-width":150,"blog-author-thumbnail-height":150,"lowres":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-100x57.jpg","lowres-width":100,"lowres-height":57,"square-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-480x480.jpg","square-md-width":480,"square-md-height":480,"rectangle-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-550x300.jpg","rectangle-md-width":550,"rectangle-md-height":300,"16x9-xs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-480x270.jpg","16x9-xs-width":480,"16x9-xs-height":270,"masthead":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-1440x400.jpg","masthead-width":1440,"masthead-height":400,"hero":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-1440x835.jpg","hero-width":1440,"hero-height":835,"hero-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-1024x768.jpg","hero-md-width":1024,"hero-md-height":768,"hero-sm":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-768x320.jpg","hero-sm-width":768,"hero-sm-height":320,"hero-xs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-460x260.jpg","hero-xs-width":460,"hero-xs-height":260,"hero-xxs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-320x260.jpg","hero-xxs-width":320,"hero-xxs-height":260,"gform-image-choice-sm":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute.jpg","gform-image-choice-sm-width":300,"gform-image-choice-sm-height":170,"gform-image-choice-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute.jpg","gform-image-choice-md-width":400,"gform-image-choice-md-height":226,"gform-image-choice-lg":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute.jpg","gform-image-choice-lg-width":600,"gform-image-choice-lg-height":339}}}],"layer_disable_gradient":false,"layer_background_color":"","layer_id":""},"feature_items_group":{"":null,"layer_label":"","layer_headline":"","layer_intro":"","layer_feature_col_width":"halves","layer_feature_has_popover":false,"layer_feature_items":false,"layer_feature_more_link":"","layer_background_color":"","layer_id":""},"content_grid_group":{"":null,"layer_label":"","layer_headline":"","layer_intro":"","layer_content_grid_col_width":"thirds","layer_content_grid_items":false,"layer_content_grid_more_link":"","layer_background_color":"","layer_id":""},"header_scripts":"\t\t\r\n{\r\n \"@context\": \"https:\/\/schema.org\",\r\n \"@graph\": [\r\n {\r\n \"@type\": \"MedicalWebPage\",\r\n \"url\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/home\/molecular-medicine\/\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/home\/molecular-medicine\/#MedicalWebPage\",\r\n \"inLanguage\": \"en-US\",\r\n \"specialty\": \"Translational Research\",\r\n \"mentions\": [\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/dave-hoon\/\",\r\n \"name\": \"Dave S.B. Hoon\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/irene-ramos\/\",\r\n \"name\": \"Irene Ramos\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/matias-bustos\/\",\r\n \"name\": \"Matias Bustos\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/yuta-kobayashi\/\",\r\n \"name\": \"Yuta Kobayashi\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/shodai-mizuno-ph-d\/\",\r\n \"name\": \"Shodai Mizuno\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/yoko-koh-md\/\",\r\n \"name\": \"Yoko Koh\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/shanty-chenathukattil\/\",\r\n \"name\": \"Shanty Chenathukattil\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/ling-takeshima\/\",\r\n \"name\": \"Ling Takeshima\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/yoshinori-hayashi-phd\/\",\r\n \"name\": \"Yoshinori Hayashi\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/jamie-moon\/\",\r\n \"name\": \"Jamie Moon\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/jose-catbagan-jr\/\",\r\n \"name\": \"Jose Catbagan\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/yuka-mizuno-m-d-ph-d\/\",\r\n \"name\": \"Yuka Mizuno\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/daniela-nasif-ph-d\/\",\r\n \"name\": \"Daniela Nasif\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/kelly-chong-ph-d\/\",\r\n \"name\": \"Kelly Chong\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\",\r\n \"name\": \"Saint John's Cancer Institute\",\r\n \"url\": \"https:\/\/www.saintjohnscancer.org\/\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ]\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/josh-gottlieb-d-o\/\",\r\n \"name\": \"Josh Gottlieb\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/safa-beg\/\",\r\n \"name\": \"Safa Beg\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/soomin-kim\/\",\r\n \"name\": \"SooMin Kim\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/sheryll-aquinde\/\",\r\n \"name\": \"Sheryll Aquinde\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n }\r\n ],\r\n \"about\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"The department of melanoma and cutaneous oncology is focused on understanding the molecular mechanisms of recurrence in early and late stages of skin cancers. Specifically, we are interested in blood and tumor biomarkers that can predict the risk of developing metastases.\",\r\n \"name\": \"Melanoma and Cutaneous Oncology\",\r\n \"associatedAnatomy\": {\r\n \"@type\": \"AnatomicalStructure\",\r\n \"name\": \"x\"\r\n }\r\n },\r\n \"isPartOf\": {\r\n \"@type\": \"WebSite\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#webpage\",\r\n \"url\": \"https:\/\/www.saintjohnscancer.org\/\",\r\n \"name\": \"Saint John's Cancer Institute\",\r\n \"keywords\": [\r\n \"Translational Molecular Medicine Research\"\r\n ],\r\n \"accessMode\": \"visual\",\r\n \"audience\": \"http:\/\/schema.org\/Patient\",\r\n \"publisher\": {\r\n \"@type\": \"MedicalOrganization\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\",\r\n \"name\": \"Saint John's Cancer Institute\",\r\n \"url\": \"https:\/\/www.saintjohnscancer.org\/\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"foundingDate\": \"1991\",\r\n \"legalName\": \"Saint John's Cancer Institute\",\r\n \"description\": \"In 1991, the John Wayne Cancer Institute launched a successful affiliation with Saint John\u2019s Health Center and opened in Santa Monica, California. Combined with the exceptional quality of Saint John\u2019s medical staff and hospital, a unique community-based cancer research and training institute was formed, outstanding in the areas of translational research and the treatment of solid tumors including surgical oncology, immunotherapy, chemotherapy, and radiation. Leading this remarkable charge was the late Donald L. Morton, M.D., a larger than life presence who was born in a rural, coal-mining town in West Virginia. His persistent, scientific questioning of the role of the immune system in fighting cancer led to many advances throughout his decorated career.\",\r\n \"logo\": {\r\n \"@type\": \"ImageObject\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#logo\",\r\n \"url\": \"https:\/\/www.saintjohnscancer.org\/wp-content\/uploads\/2021\/04\/SJCI_reverse_color-2048x512b.png\",\r\n \"caption\": \"Saint John's Cancer Institute\",\r\n \"image\": {\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#logo\"\r\n }\r\n }\r\n }\r\n }\r\n }\r\n ]\r\n}\r\n\t"},"yoast_head":"\n
Translational Molecular Medicine for Cancer Research - Santa Monica, CA | Saint John\u2019s Cancer Institute<\/title>\n<meta name=\"description\" content=\"The Department of Molecular Medicine, led by Dr. David S. B. Hoon, is focused on the development of treatment protocols for patients with solid tumor cancers.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Translational Molecular Medicine for Cancer Research - Santa Monica, CA | Saint John\u2019s Cancer Institute\" \/>\n<meta property=\"og:description\" content=\"The Department of Molecular Medicine, led by Dr. David S. B. Hoon, is focused on the development of treatment protocols for patients with solid tumor cancers.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"Translational Research\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T00:27:03+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/\",\"url\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/\",\"name\":\"Translational Molecular Medicine for Cancer Research - Santa Monica, CA | Saint John\u2019s Cancer Institute\",\"isPartOf\":{\"@id\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#website\"},\"datePublished\":\"2018-11-07T20:12:12+00:00\",\"dateModified\":\"2026-04-15T00:27:03+00:00\",\"description\":\"The Department of Molecular Medicine, led by Dr. David S. B. Hoon, is focused on the development of treatment protocols for patients with solid tumor cancers.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#website\",\"url\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/\",\"name\":\"Translational Research\",\"description\":\"Translational Research works directly with clinicians to translate lab-based discoveries into personalized treatments\",\"publisher\":{\"@id\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#organization\",\"name\":\"Translational Research\",\"url\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2024\/06\/Saint-Johns-Cancer-Institute-Home-page.png\",\"contentUrl\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2024\/06\/Saint-Johns-Cancer-Institute-Home-page.png\",\"width\":1024,\"height\":256,\"caption\":\"Translational Research\"},\"image\":{\"@id\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Translational Molecular Medicine for Cancer Research - Santa Monica, CA | Saint John\u2019s Cancer Institute","description":"The Department of Molecular Medicine, led by Dr. David S. B. Hoon, is focused on the development of treatment protocols for patients with solid tumor cancers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/","og_locale":"en_US","og_type":"article","og_title":"Translational Molecular Medicine for Cancer Research - Santa Monica, CA | Saint John\u2019s Cancer Institute","og_description":"The Department of Molecular Medicine, led by Dr. David S. B. Hoon, is focused on the development of treatment protocols for patients with solid tumor cancers.","og_url":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/","og_site_name":"Translational Research","article_modified_time":"2026-04-15T00:27:03+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/","url":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/","name":"Translational Molecular Medicine for Cancer Research - Santa Monica, CA | Saint John\u2019s Cancer Institute","isPartOf":{"@id":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#website"},"datePublished":"2018-11-07T20:12:12+00:00","dateModified":"2026-04-15T00:27:03+00:00","description":"The Department of Molecular Medicine, led by Dr. David S. B. Hoon, is focused on the development of treatment protocols for patients with solid tumor cancers.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#website","url":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/","name":"Translational Research","description":"Translational Research works directly with clinicians to translate lab-based discoveries into personalized treatments","publisher":{"@id":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#organization","name":"Translational Research","url":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#\/schema\/logo\/image\/","url":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2024\/06\/Saint-Johns-Cancer-Institute-Home-page.png","contentUrl":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2024\/06\/Saint-Johns-Cancer-Institute-Home-page.png","width":1024,"height":256,"caption":"Translational Research"},"image":{"@id":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-json\/wp\/v2\/pages\/387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-json\/wp\/v2\/comments?post=387"}],"version-history":[{"count":0,"href":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-json\/wp\/v2\/pages\/387\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-json\/wp\/v2\/media?parent=387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
- \n
- We are assessing for molecular blood biopsies in blood and urine that include cell-free nucleic acids (cfNAs) (DNA, miRNA) and CTCs and exosomes. We assess\/determine their clinical utility especially in diagnosis and prognosis during follow up of treatment.<\/li>\n
- We assess cfNA and exosomes in patients who receive immune checkpoint inhibitor therapies.<\/li>\n
- We identify various forms of epigenetic changes (methylation and histone) as related to metastasis and therapy resistance.<\/li>\n
- Our dept. assesses DNA Damage Resistance (DDR) solid tumors.<\/li>\n
- We examine primary and extracranial brain tumor cFNA and molecular biology for progression-related genes.<\/li>\n
- Our Dept has focused on proteomics as related to activity during tumor progression and DDR, specifically regulatory mechanisms of specific ubiquilin and ubiquitins.<\/li>\n
- Our studies also focus on molecular immune responses during treatment using our new approaches of spatial biology and single cell sequencing.<\/li>\n<\/ul>\n","layer_is_content_auto_columns":false,"sidebar_position":"right","widgets":false,"layer_icon":"","layer_icon_position":"left","layer_background_color":"","layer_id":""},{"acf_fc_layout":"layer_content_sidebar","layer_label":"","layer_headline":"","layer_intro":"","layer_content":"
Partnership & Collaboration<\/h2>\n
<\/p>\n<\/div>\nOur Translational Molecular Medicine Department collaborates with academic and industry partners to fulfill our translational research goals. Our academic partners help build programs, sharing knowledge and resources for the benefit of all partners, while our industry partners help us develop products and provide resources not available at the institute. The department has been supported by NIH\/NCI grants for melanoma translational studies since 1992 while support for breast cancer has been provided by FFANY, ABC, Gonda, California Breast Cancer Program, DOD, and Komen foundations. Studies in prostate cancer have been supported by ABC foundation and DOD in the past. Recent support in the last 8 years has been provided by the Adeleson Medical Research Foundation (AMRF), which includes projects related to DDR, Molecular Immunology, and Brain Metastasis as well as Epigenetic Sequence Platform Core. Additional major grant support include NCI Melanoma SPORE from the University of Penn, S. Riley Early Detection Pancreas Cancer, MiNk Therapeutics, Merck, BioDyne Inc., and the NIH NCI Preventative ROI Clinical Trial grant with the City of Hope, Duarte, CA. We are member of melanoma Melanoma SPORE: University of Pennsylvania\/Wistar Institute.<\/p>\n
Currently, the members of the department are organized in different sections of research, these include: <\/strong><\/p>\n
- \n
- The identification of cfNA and exosomes in blood and urine for diagnosis and prognosis of patients during follow-up. <\/span><\/li>\n
- The understanding of epigenetic mechanisms that regulate regional and distant(brain, visceral organ) metastasis.<\/span><\/li>\n
- Assessment of ubiquitin and ubiquilin protein regulatory pathways that promote tumor progression and treatment resistance.<\/span><\/li>\n
- Identification of mechanisms of primary brain and brain metastasis progression and tumor microenvironment interactions.<\/span><\/li>\n<\/ol>\n
- \n
- See Principle Collaborators<\/a> <\/strong><\/li>\n<\/ul>\n","layer_is_content_auto_columns":false,"sidebar_position":"right","widgets":false,"layer_icon":"","layer_icon_position":"left","layer_background_color":"bg-none","layer_id":""},{"acf_fc_layout":"layer_content_sidebar","layer_label":"","layer_headline":"","layer_intro":"","layer_content":"
The Molecular Research Team and Fellows at Saint John’s Cancer Institute<\/figcaption><\/figure>\n Postdoctoral Lab-Based Translational Molecular Medicine Fellowship<\/h2>\n
As pioneers in translational studies on \u201cmolecular fluid\u201d involving various cfNA in multiple types of solid tumors, the fellowship program also consists of studying epigenetic mechanisms, and DDR regulating solid tumors as well as pharmacogenomics and immunogenomic-based prediction of responses to therapy.<\/p>\n
Learn more about the Molecular Oncology Fellowship<\/a><\/strong><\/p>\n
News and Events<\/h2>\n
We have received a renewal of our three-year, multi-million-dollar grant from the Sheldon and Miriam Adelson Medical Research Foundation (AMRF), effective October 1, 2025. This award supports multiple national and international collaborations with major cancer centers.<\/strong>
\n<\/p>\n\nAMRF Projects<\/h3>\n
- \n
- Epigenomic and Oncogenic Drivers of Melanoma Metastasis and Therapy Resistance<\/strong><\/li>\n
- APCR\/APMMR Shared Epigenomics Resources<\/strong><\/li>\n<\/ol>\n
2024 & 2025 Conferences<\/h3>\n
- \n
- Seminar, New Melanoma Molecular Genetics Studies, Dept. Translational Molecular Medicine SJCI: January 1, 2024(Los Angeles, California)<\/strong> Speaker: Wistar Institute & University of Penn Melanoma Group.<\/li>\n
- Global Professor Seminar: Molecular and Spatial Analysis of Early Onset Colorectal Cancer (EOCRC): March, 2024 (Tokyo, Japan)<\/strong> – Speaker: Keio University of Surgery, Japan.<\/li>\n
- The 20th Ataxia-Telangiectasia Workshop March 3, 2024 (Tokyo, Japan) <\/strong> – Speaker: UBQLN4 Triggers MRE11a and STING Proteasomal Degradation During Cisplatin induced DNA Damage Response in ESCC and TNBC.<\/li>\n
- Molecular Medicine Tri-Con (31st Annual): March, 2024 (San Diego, CA)<\/strong> – Chairman and Speaker: Liquid Biopsy Biomarkers for Patient Selection and Treatment Monitoring. CFDNA ILF2 Amplification Utility in Monitoring Melanoma Patients Receiving Checkpoint Inhibitor Immunotherapy. <\/li>\n
- New Approaches in Epigenetic Platform NGS Assays: August, 2024 (Philadephia, PA)<\/strong> Dept. Obstetrics Gynecology, University of Penn.<\/li>\n
- Impact of ATM Expression on Immune Checkpoint Inhibitor Efficacy and Prognosis in Metastatic Melanoma Patients: October, 2024 (Shenzhen, China)<\/strong> ATW-2024<\/li>\n
- Special lecture: Translational Research for Surgeons. 86th Annual Congress. November, 2024 (Utsunomiya, Japan)<\/strong> Speaker: Japan Surgical Association<\/li>\n
- Presentation: Spatial Analysis of Tumor Microenvironment of Melanoma Metastasis Using NanoString GeoMx and Akoya. November, 2024 (Boston, MA)<\/strong> Speaker: Adelson Medical Research Foundation Meeting.<\/li>\n
- Presentation: Predictive Genes Signature In Primary Prostate Cancer Association with Regional Lymph-Node Metastasis Using Both mRNA and miRNA Profiling. December, 2024 <\/strong> Speaker: ESMO Asia.<\/li>\n
- Invited Speaker: Liquid Biopsy cfmiRNA. September, 2025 (Greece)<\/strong> ACTC<\/li>\n
- Invited Speaker: Liquid Biopsy cfmiRNA. December, 2025 (Hong Kong)<\/strong> CNAPS<\/li>\n<\/ul>\n<\/div>\n
Positions Available<\/h2>\n
The Department is looking for postdoctoral fellows who have experience in translational molecular CTC and cfNA research. Also postdoctoral fellows experience in Cancer Epigenetics as well as metastasis regulatory mechanisms.<\/p>\n
Contact:<\/h4>\n
<\/p>\n
Irene Ramos, MSc, Translational Molecular Medicine Department Laboratory Manager
\n<\/strong>Romela.Ramos@providence.org<\/a><\/p>\n","layer_is_content_auto_columns":false,"sidebar_position":"right","widgets":false,"layer_icon":"","layer_icon_position":"left","layer_background_color":"bg-gray-l","layer_id":""},{"acf_fc_layout":"layer_people","layer_label":"","layer_headline":"Molecular Personnel ","layer_intro":"","people":{"950":{"id":950,"title":"Irene Ramos, MSc"},"6358":{"id":6358,"title":"Tianyu Chen, MD"},"5893":{"id":5893,"title":"Kelly Chong, Ph.D"},"951":{"id":951,"title":"Ling Takeshima"},"3980":{"id":3980,"title":"Jose Catbagan Jr."},"3037":{"id":3037,"title":"Shanty Chenathukattil"},"5135":{"id":5135,"title":"Jamie Moon"},"5895":{"id":5895,"title":"SooMin Kim"},"6008":{"id":6008,"title":"Sheryll Aquinde"},"6321":{"id":6321,"title":"Kodai Abe, MD, PhD"},"6319":{"id":6319,"title":"Kazuaki Okamoto, MD, PhD"},"6775":{"id":6775,"title":"Jason Mooney"}},"layer_people_more_link":"","layer_background_color":"","layer_id":""},{"acf_fc_layout":"layer_content_image","layer_label":"","layer_headline":"","layer_content":"Publications<\/h2>\n
Key Recent Manuscripts<\/h3>\n
- \n
- Clonal dynamics shaped by diverse drug-tolerant persister states in melanoma resistance.<\/strong><\/a>. Mol Cancer. 2026 Mar 3. doi: 10.1186\/s12943-026-02622-9. PMID: 41776501\n<\/li>\n
- Ubiquitin E3 ligase KPC1 governs mesenchymal metastatic melanoma reprogramming via proteasomal degradation of ZEB1<\/strong><\/a>. Cell Death Dis. 2025 Dec 22;16(1):897. doi: 10.1038\/s41419-025-08262-z.\n<\/li>\n
- Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes<\/strong><\/a>.JCO Oncology Advances. In Press 2025.<\/li>\n
- Interruption of the Intratumor CD8: Treg Crosstalk Improves the Efficacy of PD-1 Immunotherapy.<\/strong><\/a> Cancer Cell. Jun 10;42:1051-1066.e7. doi: 10.1016\/j.ccell.2024.05.013, 2024.<\/li>\n
- Interferon-induced factor 16 is essential in metastatic melanoma to maintain STING levels and the immune responses upon IFN-\u03b3 response pathway activation.<\/strong><\/a> J Immunotherapy Cancer. Oct 18;12(10):e009590. doi: 10.1136\/jitc-2024-009590, 2024.<\/li>\n
- Induced collagen type-I secretion by hepatocytes of the melanoma liver metastasis is associated with a reduction in tumour-infiltrating lymphocytes.<\/strong><\/a> Clin Transl Med. Nov;14(11):e70067. doi: 10.1002\/ctm2.70067, 2024.<\/li>\n
- Repurposing colforsin daropate to treat MYC-driven high-grade serous ovarian carcinomas.<\/strong><\/a> Sci Signal. Nov 19;17(863):eado8303. doi: 10.1126\/scisignal.ado8303, 2024.<\/li>\n
- Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation. Cancer Cell.<\/strong><\/a> Dec 9;42(12):1985-1987. doi: 10.1016\/j.ccell.2024.10.017, 2024.<\/li>\n
- Diagnostic miRNA Signatures in Paired Tumor, Plasma, and Urine Specimens From Renal Cell Carcinoma Patients.<\/strong><\/a> Clin Chem. 2024 Jan 4;70(1):261-272. doi: 10.1093\/clinchem\/hvad133.<\/li>\n
- MRI-derived radiomics assessing tumor-infiltrating macrophages enable prediction of immune-phenotype, immunotherapy response and survival in glioma<\/strong><\/a> Biomark Res. 2024 Jan 31;12(1):14. doi: 10.1186\/s40364-024-00560-6.<\/li>\n
- Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells<\/strong><\/a> JCI Insight. 2024 Mar 8;9(5):e170961. doi: 10.1172\/jci.insight.170961.<\/li>\n
- Preanalytical considerations in quantifying circulating miRNAs that predict end-stage kidney disease in diabetes<\/strong><\/a> JCI Insight. 2024 Jun 24;9(12):e174153. doi: 10.1172\/jci.insight.174153.<\/li>\n
- Tissue-specific thresholds of mutation burden associated with anti-PD-1\/L1 therapy benefit and prognosis in microsatellite-stable cancers<\/strong><\/a> Nat Cancer. 2024 Jul;5(7):1121-1129. doi: 10.1038\/s43018-024-00752-x. Epub 2024 Mar 25.<\/li>\n
- Smoking Status and Survival in Patients With Early-Stage Primary Cutaneous Melanoma<\/strong><\/a> JAMA Netw Open. 2024 Feb 5;7(2):e2354751. doi: 10.1001\/jamanetworkopen.2023.54751.<\/li>\n
- Spatial profiling of cancer-associated fibroblasts of sporadic early onset colon cancer microenvironment<\/strong><\/a> NPJ Precis Oncol. 2023 Nov 14;7(1):118. doi: 10.1038\/s41698-023-00474-w.<\/li>\n
- Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases<\/strong><\/a> NPJ Precis Oncol. 2023 Nov 14;7(1):120. doi: 10.1038\/s41698-023-00471-z.<\/li>\n
- Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma.<\/strong><\/a> Clin Cancer Res, 28, 1911\u201324, 2022.<\/li>\n
- Topical therapy for regression and melanoma prevention of congenital giant nevi.<\/strong><\/a> Cell, 185, 2071\u201385. e12, 2022.\n
- Integrated analysis of plasma and single immune cells uncovers metabolic changes in individuals with COVID-19<\/strong><\/a>. Nat Biotechnol. 2022 Jan;40(1):110-120. doi: 10.1038\/s41587-021-01020-4.<\/li>\n
- Multi-modal molecular programs regulate melanoma cell state.<\/strong><\/a> Nat Commun. 2022 Jul 9;13(1):4000. doi: 10.1038\/s41467-022-31510-1.<\/li>\n
- IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer.<\/strong><\/a> Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2201376119. doi: 10.1073\/pnas.2201376119.<\/li>\n<\/ul>\n","layer_link":"","layer_img":1448,"layer_img_position":"left","layer_img_size":"cover","layer_img_is_fade":false,"layer_background_color":"bg-gray-l","layer_id":""}],"int_alt_page_title":"","int_page_description":"","int_masthead_image":false,"int_page_icon":"","int_secondary_cta_override":false,"int_secondary_cta_is_hidden":true,"hero_group":{"":null,"layer_hero_headline":"Translational Molecular Medicine Research","layer_hero_excerpt":"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses. Our team translates promising therapeutics from bench to bedside treatment for solid tumors, particularly melanoma, breast cancer, GU cancer, GI tract cancers and brain tumors.","layer_hero_link":"","layer_hero_images":[{"layer_hero_img":{"ID":1210,"id":1210,"title":"translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide","filename":"translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-scaled.jpg","filesize":372079,"url":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-scaled.jpg","link":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide\/","alt":"Translational Molecular Medicine - Bio-Markers - Saint John's Cancer Institute","author":"62","description":"","caption":"","name":"translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide","status":"inherit","uploaded_to":387,"date":"2021-05-10 21:49:01","modified":"2021-05-10 21:49:11","menu_order":0,"mime_type":"image\/jpeg","type":"image","subtype":"jpeg","icon":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-includes\/images\/media\/default.png","width":2560,"height":1190,"sizes":{"thumbnail":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-150x150.jpg","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-300x139.jpg","medium-width":300,"medium-height":139,"medium_large":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-768x357.jpg","medium_large-width":768,"medium_large-height":357,"large":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-1024x476.jpg","large-width":1024,"large-height":476,"1536x1536":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-1536x714.jpg","1536x1536-width":1536,"1536x1536-height":714,"2048x2048":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-2048x952.jpg","2048x2048-width":2048,"2048x2048-height":952,"blog-author-thumbnail":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-150x150.jpg","blog-author-thumbnail-width":150,"blog-author-thumbnail-height":150,"lowres":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-100x46.jpg","lowres-width":100,"lowres-height":46,"square-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-480x480.jpg","square-md-width":480,"square-md-height":480,"rectangle-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-550x300.jpg","rectangle-md-width":550,"rectangle-md-height":300,"16x9-xs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-480x270.jpg","16x9-xs-width":480,"16x9-xs-height":270,"masthead":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-1440x400.jpg","masthead-width":1440,"masthead-height":400,"hero":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-1440x835.jpg","hero-width":1440,"hero-height":835,"hero-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-1024x768.jpg","hero-md-width":1024,"hero-md-height":768,"hero-sm":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-768x320.jpg","hero-sm-width":768,"hero-sm-height":320,"hero-xs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-460x260.jpg","hero-xs-width":460,"hero-xs-height":260,"hero-xxs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-320x260.jpg","hero-xxs-width":320,"hero-xxs-height":260,"gform-image-choice-sm":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-scaled.jpg","gform-image-choice-sm-width":300,"gform-image-choice-sm-height":139,"gform-image-choice-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-scaled.jpg","gform-image-choice-md-width":400,"gform-image-choice-md-height":186,"gform-image-choice-lg":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/translational-molecular-medicine-bio-markers-saint-johns-cancer-institute-wide-scaled.jpg","gform-image-choice-lg-width":600,"gform-image-choice-lg-height":279}}},{"layer_hero_img":false},{"layer_hero_img":{"ID":1246,"id":1246,"title":"HTG-Edge-Sequencing--saint-johns-cancer-institute","filename":"HTG-Edge-Sequencing-saint-johns-cancer-institute.jpg","filesize":714300,"url":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute.jpg","link":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/htg-edge-sequencing-saint-johns-cancer-institute\/","alt":"Genetic Sequencing -Saint Johns Cancer Institute","author":"62","description":"","caption":"","name":"htg-edge-sequencing-saint-johns-cancer-institute","status":"inherit","uploaded_to":387,"date":"2021-05-17 21:27:37","modified":"2021-05-17 21:28:24","menu_order":0,"mime_type":"image\/jpeg","type":"image","subtype":"jpeg","icon":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-includes\/images\/media\/default.png","width":2074,"height":1555,"sizes":{"thumbnail":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-150x150.jpg","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-300x225.jpg","medium-width":300,"medium-height":225,"medium_large":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-768x576.jpg","medium_large-width":768,"medium_large-height":576,"large":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-1024x768.jpg","large-width":1024,"large-height":768,"1536x1536":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-1536x1152.jpg","1536x1536-width":1536,"1536x1536-height":1152,"2048x2048":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-2048x1536.jpg","2048x2048-width":2048,"2048x2048-height":1536,"blog-author-thumbnail":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-150x150.jpg","blog-author-thumbnail-width":150,"blog-author-thumbnail-height":150,"lowres":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-100x75.jpg","lowres-width":100,"lowres-height":75,"square-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-480x480.jpg","square-md-width":480,"square-md-height":480,"rectangle-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-550x300.jpg","rectangle-md-width":550,"rectangle-md-height":300,"16x9-xs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-480x270.jpg","16x9-xs-width":480,"16x9-xs-height":270,"masthead":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-1440x400.jpg","masthead-width":1440,"masthead-height":400,"hero":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-1440x835.jpg","hero-width":1440,"hero-height":835,"hero-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-1024x768.jpg","hero-md-width":1024,"hero-md-height":768,"hero-sm":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-768x320.jpg","hero-sm-width":768,"hero-sm-height":320,"hero-xs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-460x260.jpg","hero-xs-width":460,"hero-xs-height":260,"hero-xxs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute-320x260.jpg","hero-xxs-width":320,"hero-xxs-height":260,"gform-image-choice-sm":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute.jpg","gform-image-choice-sm-width":300,"gform-image-choice-sm-height":225,"gform-image-choice-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute.jpg","gform-image-choice-md-width":400,"gform-image-choice-md-height":300,"gform-image-choice-lg":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-Edge-Sequencing-saint-johns-cancer-institute.jpg","gform-image-choice-lg-width":600,"gform-image-choice-lg-height":450}}},{"layer_hero_img":{"ID":1245,"id":1245,"title":"HTG-molecular-saint-johns-cancer-institute","filename":"HTG-molecular-saint-johns-cancer-institute.jpg","filesize":1361052,"url":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute.jpg","link":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/htg-molecular-saint-johns-cancer-institute\/","alt":"HTG Molecular Saint Johns Cancer Institute","author":"62","description":"","caption":"","name":"htg-molecular-saint-johns-cancer-institute","status":"inherit","uploaded_to":387,"date":"2021-05-17 20:23:08","modified":"2021-05-17 20:25:16","menu_order":0,"mime_type":"image\/jpeg","type":"image","subtype":"jpeg","icon":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-includes\/images\/media\/default.png","width":2074,"height":1172,"sizes":{"thumbnail":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-150x150.jpg","thumbnail-width":150,"thumbnail-height":150,"medium":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-300x170.jpg","medium-width":300,"medium-height":170,"medium_large":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-768x434.jpg","medium_large-width":768,"medium_large-height":434,"large":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-1024x579.jpg","large-width":1024,"large-height":579,"1536x1536":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-1536x868.jpg","1536x1536-width":1536,"1536x1536-height":868,"2048x2048":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-2048x1157.jpg","2048x2048-width":2048,"2048x2048-height":1157,"blog-author-thumbnail":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-150x150.jpg","blog-author-thumbnail-width":150,"blog-author-thumbnail-height":150,"lowres":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-100x57.jpg","lowres-width":100,"lowres-height":57,"square-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-480x480.jpg","square-md-width":480,"square-md-height":480,"rectangle-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-550x300.jpg","rectangle-md-width":550,"rectangle-md-height":300,"16x9-xs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-480x270.jpg","16x9-xs-width":480,"16x9-xs-height":270,"masthead":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-1440x400.jpg","masthead-width":1440,"masthead-height":400,"hero":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-1440x835.jpg","hero-width":1440,"hero-height":835,"hero-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-1024x768.jpg","hero-md-width":1024,"hero-md-height":768,"hero-sm":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-768x320.jpg","hero-sm-width":768,"hero-sm-height":320,"hero-xs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-460x260.jpg","hero-xs-width":460,"hero-xs-height":260,"hero-xxs":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute-320x260.jpg","hero-xxs-width":320,"hero-xxs-height":260,"gform-image-choice-sm":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute.jpg","gform-image-choice-sm-width":300,"gform-image-choice-sm-height":170,"gform-image-choice-md":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute.jpg","gform-image-choice-md-width":400,"gform-image-choice-md-height":226,"gform-image-choice-lg":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2021\/05\/HTG-molecular-saint-johns-cancer-institute.jpg","gform-image-choice-lg-width":600,"gform-image-choice-lg-height":339}}}],"layer_disable_gradient":false,"layer_background_color":"","layer_id":""},"feature_items_group":{"":null,"layer_label":"","layer_headline":"","layer_intro":"","layer_feature_col_width":"halves","layer_feature_has_popover":false,"layer_feature_items":false,"layer_feature_more_link":"","layer_background_color":"","layer_id":""},"content_grid_group":{"":null,"layer_label":"","layer_headline":"","layer_intro":"","layer_content_grid_col_width":"thirds","layer_content_grid_items":false,"layer_content_grid_more_link":"","layer_background_color":"","layer_id":""},"header_scripts":"\t\t\r\n{\r\n \"@context\": \"https:\/\/schema.org\",\r\n \"@graph\": [\r\n {\r\n \"@type\": \"MedicalWebPage\",\r\n \"url\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/home\/molecular-medicine\/\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/home\/molecular-medicine\/#MedicalWebPage\",\r\n \"inLanguage\": \"en-US\",\r\n \"specialty\": \"Translational Research\",\r\n \"mentions\": [\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/dave-hoon\/\",\r\n \"name\": \"Dave S.B. Hoon\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/irene-ramos\/\",\r\n \"name\": \"Irene Ramos\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/matias-bustos\/\",\r\n \"name\": \"Matias Bustos\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/yuta-kobayashi\/\",\r\n \"name\": \"Yuta Kobayashi\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/shodai-mizuno-ph-d\/\",\r\n \"name\": \"Shodai Mizuno\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/yoko-koh-md\/\",\r\n \"name\": \"Yoko Koh\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/shanty-chenathukattil\/\",\r\n \"name\": \"Shanty Chenathukattil\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/ling-takeshima\/\",\r\n \"name\": \"Ling Takeshima\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/yoshinori-hayashi-phd\/\",\r\n \"name\": \"Yoshinori Hayashi\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/jamie-moon\/\",\r\n \"name\": \"Jamie Moon\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/jose-catbagan-jr\/\",\r\n \"name\": \"Jose Catbagan\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/yuka-mizuno-m-d-ph-d\/\",\r\n \"name\": \"Yuka Mizuno\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/daniela-nasif-ph-d\/\",\r\n \"name\": \"Daniela Nasif\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/kelly-chong-ph-d\/\",\r\n \"name\": \"Kelly Chong\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\",\r\n \"name\": \"Saint John's Cancer Institute\",\r\n \"url\": \"https:\/\/www.saintjohnscancer.org\/\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ]\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/josh-gottlieb-d-o\/\",\r\n \"name\": \"Josh Gottlieb\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/safa-beg\/\",\r\n \"name\": \"Safa Beg\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/soomin-kim\/\",\r\n \"name\": \"SooMin Kim\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n },\r\n {\r\n \"@type\": \"Physician\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/meet-our-team\/sheryll-aquinde\/\",\r\n \"name\": \"Sheryll Aquinde\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"knowsAbout\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"Translational Molecular Medicine is focused on translational application of transcriptomic, genomic, and epigenomic cancer biomarkers using Next Generation Sequencing in tissue and body fluids. Also, we focus on DNA Damage Response (CDDR) as related to Drug Resistance and Immune Responses\",\r\n \"name\": \"Translational Molecular Medicine Research\"\r\n },\r\n \"hospitalAffiliation\": {\r\n \"@type\": \"Hospital\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\"\r\n }\r\n }\r\n ],\r\n \"about\": {\r\n \"@type\": \"MedicalCondition\",\r\n \"description\": \"The department of melanoma and cutaneous oncology is focused on understanding the molecular mechanisms of recurrence in early and late stages of skin cancers. Specifically, we are interested in blood and tumor biomarkers that can predict the risk of developing metastases.\",\r\n \"name\": \"Melanoma and Cutaneous Oncology\",\r\n \"associatedAnatomy\": {\r\n \"@type\": \"AnatomicalStructure\",\r\n \"name\": \"x\"\r\n }\r\n },\r\n \"isPartOf\": {\r\n \"@type\": \"WebSite\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#webpage\",\r\n \"url\": \"https:\/\/www.saintjohnscancer.org\/\",\r\n \"name\": \"Saint John's Cancer Institute\",\r\n \"keywords\": [\r\n \"Translational Molecular Medicine Research\"\r\n ],\r\n \"accessMode\": \"visual\",\r\n \"audience\": \"http:\/\/schema.org\/Patient\",\r\n \"publisher\": {\r\n \"@type\": \"MedicalOrganization\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#MedicalOrganization\",\r\n \"name\": \"Saint John's Cancer Institute\",\r\n \"url\": \"https:\/\/www.saintjohnscancer.org\/\",\r\n \"address\": {\r\n \"@type\": \"PostalAddress\",\r\n \"addressLocality\": \"Santa Monica\",\r\n \"addressRegion\": \"CA\",\r\n \"postalCode\": \"90404\",\r\n \"streetAddress\": \"2200 Santa Monica\"\r\n },\r\n \"areaServed\": \"US\",\r\n \"contactPoint\": [\r\n {\r\n \"@type\": \"ContactPoint\",\r\n \"telephone\": \"+1-310-315-6125\",\r\n \"contactType\": \"Main Facility\"\r\n }\r\n ],\r\n \"foundingDate\": \"1991\",\r\n \"legalName\": \"Saint John's Cancer Institute\",\r\n \"description\": \"In 1991, the John Wayne Cancer Institute launched a successful affiliation with Saint John\u2019s Health Center and opened in Santa Monica, California. Combined with the exceptional quality of Saint John\u2019s medical staff and hospital, a unique community-based cancer research and training institute was formed, outstanding in the areas of translational research and the treatment of solid tumors including surgical oncology, immunotherapy, chemotherapy, and radiation. Leading this remarkable charge was the late Donald L. Morton, M.D., a larger than life presence who was born in a rural, coal-mining town in West Virginia. His persistent, scientific questioning of the role of the immune system in fighting cancer led to many advances throughout his decorated career.\",\r\n \"logo\": {\r\n \"@type\": \"ImageObject\",\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#logo\",\r\n \"url\": \"https:\/\/www.saintjohnscancer.org\/wp-content\/uploads\/2021\/04\/SJCI_reverse_color-2048x512b.png\",\r\n \"caption\": \"Saint John's Cancer Institute\",\r\n \"image\": {\r\n \"@id\": \"https:\/\/www.saintjohnscancer.org\/#logo\"\r\n }\r\n }\r\n }\r\n }\r\n }\r\n ]\r\n}\r\n\t"},"yoast_head":"\n
Translational Molecular Medicine for Cancer Research - Santa Monica, CA | Saint John\u2019s Cancer Institute<\/title>\n<meta name=\"description\" content=\"The Department of Molecular Medicine, led by Dr. David S. B. Hoon, is focused on the development of treatment protocols for patients with solid tumor cancers.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Translational Molecular Medicine for Cancer Research - Santa Monica, CA | Saint John\u2019s Cancer Institute\" \/>\n<meta property=\"og:description\" content=\"The Department of Molecular Medicine, led by Dr. David S. B. Hoon, is focused on the development of treatment protocols for patients with solid tumor cancers.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"Translational Research\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T00:27:03+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/\",\"url\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/\",\"name\":\"Translational Molecular Medicine for Cancer Research - Santa Monica, CA | Saint John\u2019s Cancer Institute\",\"isPartOf\":{\"@id\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#website\"},\"datePublished\":\"2018-11-07T20:12:12+00:00\",\"dateModified\":\"2026-04-15T00:27:03+00:00\",\"description\":\"The Department of Molecular Medicine, led by Dr. David S. B. Hoon, is focused on the development of treatment protocols for patients with solid tumor cancers.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#website\",\"url\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/\",\"name\":\"Translational Research\",\"description\":\"Translational Research works directly with clinicians to translate lab-based discoveries into personalized treatments\",\"publisher\":{\"@id\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#organization\",\"name\":\"Translational Research\",\"url\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2024\/06\/Saint-Johns-Cancer-Institute-Home-page.png\",\"contentUrl\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2024\/06\/Saint-Johns-Cancer-Institute-Home-page.png\",\"width\":1024,\"height\":256,\"caption\":\"Translational Research\"},\"image\":{\"@id\":\"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Translational Molecular Medicine for Cancer Research - Santa Monica, CA | Saint John\u2019s Cancer Institute","description":"The Department of Molecular Medicine, led by Dr. David S. B. Hoon, is focused on the development of treatment protocols for patients with solid tumor cancers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/","og_locale":"en_US","og_type":"article","og_title":"Translational Molecular Medicine for Cancer Research - Santa Monica, CA | Saint John\u2019s Cancer Institute","og_description":"The Department of Molecular Medicine, led by Dr. David S. B. Hoon, is focused on the development of treatment protocols for patients with solid tumor cancers.","og_url":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/","og_site_name":"Translational Research","article_modified_time":"2026-04-15T00:27:03+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/","url":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/","name":"Translational Molecular Medicine for Cancer Research - Santa Monica, CA | Saint John\u2019s Cancer Institute","isPartOf":{"@id":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#website"},"datePublished":"2018-11-07T20:12:12+00:00","dateModified":"2026-04-15T00:27:03+00:00","description":"The Department of Molecular Medicine, led by Dr. David S. B. Hoon, is focused on the development of treatment protocols for patients with solid tumor cancers.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.saintjohnscancer.org\/translational-research-departments\/molecular-medicine\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#website","url":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/","name":"Translational Research","description":"Translational Research works directly with clinicians to translate lab-based discoveries into personalized treatments","publisher":{"@id":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#organization","name":"Translational Research","url":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#\/schema\/logo\/image\/","url":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2024\/06\/Saint-Johns-Cancer-Institute-Home-page.png","contentUrl":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-content\/uploads\/sites\/9\/2024\/06\/Saint-Johns-Cancer-Institute-Home-page.png","width":1024,"height":256,"caption":"Translational Research"},"image":{"@id":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-json\/wp\/v2\/pages\/387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-json\/wp\/v2\/comments?post=387"}],"version-history":[{"count":0,"href":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-json\/wp\/v2\/pages\/387\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.saintjohnscancer.org\/translational-research-departments\/wp-json\/wp\/v2\/media?parent=387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} - Ubiquitin E3 ligase KPC1 governs mesenchymal metastatic melanoma reprogramming via proteasomal degradation of ZEB1<\/strong><\/a>. Cell Death Dis. 2025 Dec 22;16(1):897. doi: 10.1038\/s41419-025-08262-z.\n<\/li>\n
- Global Professor Seminar: Molecular and Spatial Analysis of Early Onset Colorectal Cancer (EOCRC): March, 2024 (Tokyo, Japan)<\/strong> – Speaker: Keio University of Surgery, Japan.<\/li>\n
- APCR\/APMMR Shared Epigenomics Resources<\/strong><\/li>\n<\/ol>\n
- Epigenomic and Oncogenic Drivers of Melanoma Metastasis and Therapy Resistance<\/strong><\/li>\n
- The understanding of epigenetic mechanisms that regulate regional and distant(brain, visceral organ) metastasis.<\/span><\/li>\n
- The identification of cfNA and exosomes in blood and urine for diagnosis and prognosis of patients during follow-up. <\/span><\/li>\n